The IL-6/sIL-6R treatment of a malignant melanoma cell line enhances susceptibility to TNF-α-induced apoptosis

Melanoma is an intractable tumor that has shown very impressive and promising response to local administration of high dose recombinant TNF-α in combination with IFN-γ in clinical studies. In this study, we investigated the effect of IL-6/sIL-6R on TNF-α-resistant B16/F10.9 melanoma cells. A low dos...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2007-03, Vol.354 (4), p.985-991
Main Authors: Wagley, Yadav, Yoo, Yung-Choon, Seo, Han Geuk, Rhee, Man Hee, Kim, Tae-Hyoung, Kang, Keon Wook, Nah, Seung-Yeol, Oh, Jae-Wook
Format: Article
Language:English
Subjects:
Animals
Apoptosis
Apoptosis - drug effects
Bcl-2
Caspase-3
Cell Line, Tumor
Cell Proliferation - drug effects
Cytokine Receptor gp130 - physiology
Drug Synergism
IL-6
Interleukin-6 - therapeutic use
Melanoma - drug therapy
Mice
Proto-Oncogene Proteins c-bcl-2 - biosynthesis
Receptors, Interleukin-6 - therapeutic use
Receptors, Tumor Necrosis Factor, Type II - biosynthesis
Receptors, Tumor Necrosis Factor, Type II - immunology
Recombinant Fusion Proteins - therapeutic use
sIL-6R
Solubility
TNF-R55
TNF-α
Tumor Necrosis Factor-alpha - pharmacology
Up-Regulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Melanoma is an intractable tumor that has shown very impressive and promising response to local administration of high dose recombinant TNF-α in combination with IFN-γ in clinical studies. In this study, we investigated the effect of IL-6/sIL-6R on TNF-α-resistant B16/F10.9 melanoma cells. A low dose of TNF-α or IL-6/sIL-6R had minimal affect on the cell growth. However, the highly active fusion protein of sIL-6R and IL-6 (IL6RIL6), covalently linked by a flexible peptide, sensitized TNF-α-resistant F10.9 melanoma cells to TNF-α-induced apoptosis. Stimulation of the cells with IL6RIL6 plus TNF-α resulted in both the activation of caspase-3 and the reduction of bcl-2 expression. Flow cytometry analysis showed that IL6RIL6-upregulated TNF-R55 and TNF-R75 expression, suggesting an increase in TNF-α responsiveness by IL6RIL6 resulting from the induction of TNF receptors. Moreover, exposure of F10.9 cells to neutralizing antibody to TNF-R55 significantly inhibited IL6RIL6/TNF-α-induced cytotoxicity. These results suggest that the IL6/sIL6R/gp130 system, which sensitizes TNF-α-resistant melanoma cells to TNF-α-induced apoptosis, may provide a new target for immunotherapy.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2007.01.083